Kiora Initiates Phase 2 Clinical Trial For Retinal Macular Edema Treatment

Kiora Pharmaceuticals has received regulatory approval to launch the Phase 2 KLARITY clinical trial of KIO-104, an experimental drug for retinal macular edema, a condition that leads to fluid buildup behind the retina and vision impairment. KIO-104 offers a promising alternative to traditional treatments like steroids and systemic anti-inflammatory drugs, which are often associated with side effects. The drug works by targeting T cells and inhibiting the enzyme DHODH, reducing inflammation in the eye. Kiora aims to provide a steroid-sparing, localized treatment for this challenging condition.

The KLARITY trial will involve up to 28 participants at multiple sites and will assess the safety, tolerability, and efficacy of KIO-104 through repeated eye injections. The study will be conducted in two phases: the first part will focus on dose optimization with two different dosages, and the second part will explore dosing schedules, comparing injections every two versus four weeks. Dr. Eric J. Daniels, Chief Development Officer at Kiora, emphasized the potential of KIO-104 to significantly benefit patients with macular edema and highlighted the drug's clinically validated immunomodulatory pathway, which has proven successful in treating other inflammatory conditions like multiple sclerosis and rheumatoid arthritis.